Neal I. Muni
Chief Operating Officer at Comera Life Sciences, Inc.
Net worth: - $ as of 31/03/2024
Profile
Neal I.
Muni is currently the Director at CutisPharma Holdings, Inc. and the Chief Operating Officer at Comera Life Sciences, Inc. He was previously the Chief Executive Officer at Azurity Pharmaceuticals, Inc. from 2014 to 2020 and the Chief Operating Officer & Executive VP at Comera Life Sciences Holdings, Inc. He received his undergraduate degree from Brown University and his graduate and doctorate degrees from Tulane University School of Medicine.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
14/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Neal I. Muni active positions
Companies | Position | Start |
---|---|---|
CutisPharma Holdings, Inc.
CutisPharma Holdings, Inc. Pharmaceuticals: MajorHealth Technology CutisPharma Holdings, Inc. operates in the pharmaceuticals industry. The company is headquartered in Raleigh, NC. | Director/Board Member | - |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a private company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | Chief Operating Officer | - |
Former positions of Neal I. Muni
Companies | Position | End |
---|---|---|
COMERA LIFE SCIENCES HOLDINGS, INC. | Chief Operating Officer | 06/10/2023 |
Azurity Pharmaceuticals, Inc.
Azurity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azurity Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on the needs of patients, especially children and the elderly, requiring customized, user-friendly drug formulations. The firm?s products include Epaned, Qbrelis, Xatmep and FIRVANQ oral solutions. The company was founded in 1998 and is headquartered in Woburn, MA. | Chief Executive Officer | 01/01/2020 |
Training of Neal I. Muni
Brown University | Undergraduate Degree |
Tulane University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
COMERA LIFE SCIENCES HOLDINGS, INC. | Health Technology |
Private companies | 3 |
---|---|
CutisPharma Holdings, Inc.
CutisPharma Holdings, Inc. Pharmaceuticals: MajorHealth Technology CutisPharma Holdings, Inc. operates in the pharmaceuticals industry. The company is headquartered in Raleigh, NC. | Health Technology |
Azurity Pharmaceuticals, Inc.
Azurity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azurity Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on the needs of patients, especially children and the elderly, requiring customized, user-friendly drug formulations. The firm?s products include Epaned, Qbrelis, Xatmep and FIRVANQ oral solutions. The company was founded in 1998 and is headquartered in Woburn, MA. | Health Technology |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a private company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | Health Technology |
- Stock Market
- Insiders
- Neal I. Muni